Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 6/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044970 | 0.81 | LMNA (0.41) | MAOAMAOBALOX5LMNAGAA | |
| SCHEMBL855164 | 0.81 | MAOA (0.38) | MAOAMAOBALOX5LMNAGAA | |
| SCHEMBL20811853 | 0.81 | KCNJ1 (0.40) | MAOAMAOBALOX5ALDH1A1LMNA | |
| SCHEMBL855294 | 0.81 | MAOA (0.38) | MAOAMAOBALOX5LMNAGAA | |
| SCHEMBL3873999 | 0.78 | MAOA (0.41) | MAOAMAOBALOX5PDE3BPDE3A | |
| SCHEMBL14727441 | 0.77 | MAOA (0.38) | MAOAMAOBALOX5KCNJ1PDE3B | |
| SCHEMBL854099 | 0.76 | ALOX5 (0.39) | MAOAMAOBALOX5ALDH1A1LMNA | |
| SCHEMBL2049186 | 0.75 | PGR (0.41) | MAOAMAOBALOX5ALDH1A1PGR | |
| SCHEMBL29947934 | 0.75 | PGR (0.41) | MAOAMAOBALOX5ALDH1A1PGR | |
| SCHEMBL25354432 | 0.74 | TGM2 (0.39) | TGM2MAOAMAOBLOXPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105849094-B | The manufacture method of halogen-substituted phthalein | 住友化学株式会社 | 2018-04-10 | — | — | CN | disclosed |
| CN-105849094-A | Method for producing halogen-substituted phthalide | 住友化学株式会社 | 2016-08-10 | — | — | CN | disclosed |
| US-8604221-B2 | Production method of halogen-substituted phthalide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120142946-A1 | PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2433933-A1 | PRODUCTION METHOD OF HALOGEN-SUBSTITUTED PHTHALIDE | Sumitomo Chemical Company, Limited (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP3 | TGM2 2893/4885MAOA 587/4885MAOB 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.